CTOs on the Move

Crinetics

www.crinetics.com

 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.crinetics.com
  • 10222 Barnes Canyon Road Building 2
    San Diego, CA USA 92121
  • Phone: 858.450.6464

Executives

Name Title Contact Details

Funding

Crinetics raised $40M on 11/02/2015

Similar Companies

Vidara Therapeutics

Vidara Therapeutics is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scrippshealth

Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spero Therapeutics

Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.

Oncology Plus

Oncology Plus is a Brandon, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CellzDirect Inc

CellzDirect Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.